Lilly, for instance, already markets tirzepatide and is also banking on orforglipron, a once-daily small-molecule GLP-1 agonist that can be taken as a pill
Researchers believe this reduction may partly contribute to slower healing, collagen loss, inflammation, tissue degeneration, and visible signs of aging
Hypothetical Dosing Considerations While no evidence-based cagrilintide dosage with retatrutide protocol exists, theoretical frameworks based on monotherapy data suggest several principles that would likely apply: Conservative Approach Principles: Start with minimal doses Perhaps 0.3 mg cagrilintide + 2 mg retatrutide weekly Extended titration periods 16-24 weeks to reach target doses instead of standard 8-12 weeks Alternating escalation Increase one compound while holding the other stable Frequent monitoring Weekly check-ins during initial phases Lower maximum doses Perhaps 1.2 mg cagrilintide + 8 mg retatrutide rather than maximum monotherapy doses These suggestions remain purely speculative and should not be interpreted as clinical recommendations
Defy Medical (2026) 4
Keep locked and away from children
Employment status also influences treatment adherence, as research shows employed individuals demonstrate higher completion rates